We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Graft Polymer (uk) Plc | LSE:GPL | London | Ordinary Share | GB00BMD1Z199 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.165 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.16 | 0.17 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 587k | -3.12M | -0.0014 | -1.14 | 3.79M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.165 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 14/1/2025 | 07:00 | UK RNS | Graft Polymer (UK) PLC Change of Name to Solvonis Therapeutics plc |
| 06/1/2025 | 21:34 | ALNC |  TRADING UPDATES: Minoan in debt talks; Sealand perplexed by share rise |
| 06/1/2025 | 14:27 | UK RNS | Graft Polymer (UK) PLC Result of General Meeting and change of name |
| 18/12/2024 | 07:00 | UK RNS | Graft Polymer (UK) PLC Proactive Investors Interview with CEO and Chair |
| 16/12/2024 | 07:00 | UK RNS | Graft Polymer (UK) PLC Proposed acquisition of Awakn Life Sciences Corp |
| 11/12/2024 | 07:00 | UK RNS | Graft Polymer (UK) PLC Initial Results University of Nottingham |
| 03/12/2024 | 09:44 | UK RNS | Graft Polymer (UK) PLC Notice of GM and proposed name change |
| 15/10/2024 | 13:22 | ALNC | TRADING UPDATES: Strategic Minerals touts improved Cobre sales |
| 15/10/2024 | 06:00 | UK RNS | Graft Polymer (UK) PLC Research Agreement |
| 04/10/2024 | 18:10 | ALNC | IN BRIEF: Graft Polymer selects Eurfins to test aminoindane series |
Graft Polymer (uk) (GPL) Share Charts1 Year Graft Polymer (uk) Chart |
|
1 Month Graft Polymer (uk) Chart |
Intraday Graft Polymer (uk) Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 24/1/2025 | 15:21 | Grafting Graft Polymer | 772 |
| 16/7/2024 | 06:23 | Beware of this scam | 20 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 06/2/2025 08:20 by Graft Polymer (uk) Daily Update Graft Polymer (uk) Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GPL. The last closing price for Graft Polymer (uk) was 0.17p.Graft Polymer (uk) currently has 2,295,930,633 shares in issue. The market capitalisation of Graft Polymer (uk) is £3,673,489. Graft Polymer (uk) has a price to earnings ratio (PE ratio) of -1.14. This morning GPL shares opened at - |
Posted at 24/1/2025 15:21 by mello2024 Just to let shareholders and prospective investors know that Solvonis Therapeutics (formerly Graft Polymer) will be presenting on the MelloMonday webinar at 4.30pm on the 27th January, 2025. The programme for the evening is as follows: 4.30pm Interview with Fund Manager, Katen Patel 5:00pm Company presentation from Helios Underwriting plc 5:40pm Company presentation from Solvonis Therapeutics (formerly Graft Polymer) 6.20pm Educational session 6:35pm Company presentation from Cohort plc 7:05pm BASH (Buy, Avoid, Sell Hold) Panel featuring Kevin Taylor and Mark Simpson Tickets are still available and if you would like one at half price then enter the code MMTADVFN50. |
Posted at 16/12/2024 11:40 by bri15 Tips for 2025, obviously GPL,plus FAB,ROCK,GSCU,GENF and possibly WCAT. |
Posted at 11/12/2024 07:44 by ssrover great result at #GPL The potential here is off the scale.Sub £5 mil Mcap for what we have here is, and let’s be honest here quite simply ridiculous. X that by 10 and I’d still feel super comfy given the global potential of these therapeutics, and the currently unmet need medical for these disorders. could be todays bagger or two |
Posted at 15/11/2024 15:07 by ssrover #GPL about to blast off.. full ask for small.. something defiantly brewing here.. literally no noise on twitter and bulletin boards |
Posted at 15/11/2024 13:02 by ssrover GPL near full ask now 21.98p.. reckon this goes again this afternoon awaiting news next week possibly even monday |
Posted at 14/11/2024 20:39 by ssrover #GPL in fact the more i think about it the more i feel #GPL is about to moon.. this deal in the same sector is incredible .. #GPL market cap £4m.. this deal is worth £2billion |
Posted at 14/11/2024 16:21 by ssrover #GPL days highs paid and 100m volume and zero interest on twitter and bulletin boards.. suggest someone is loading heavy prior to clinical trials due anytime.. last time it went from 0.1p to over 1p in two days |
Posted at 14/11/2024 09:11 by ssrover Myles McNulty@MylesMcNulty Graft Polymer #GPL has been climbing quietly under the radar the past three weeks, following the major pullback in the latter half of October. Now +50% since the lows. Definitely a buyer or two around. Do they know something? Probably. Eurofins study results due any day now, and I suspect new chairman Dennis Purcell has also been busy on new introductions and deals. As previously stated, I get the impression Dennis wants GPL as his preferred listed vehicle focusing on mental disorders. A mammoth new frontier in biotech. Graft Polymer’s existing technology is just the start for the Group. Quote |
Posted at 14/11/2024 09:08 by ssrover A very quick turnaround anticipated for this pre-clinical study being carried out by Eurofins on behalf of #GPL - possibly as fast as two weeks."The focus of this joint programme (with Awakn) is the development of next-generation medicines targeting trauma-related mental health conditions, such as Post-Traumatic Stress Disorder ("PTSD"), a condition affecting approximately 13 million adults in the U.S. and 20 million individuals across the US, UK, and key European markets. The aminoindane series being developed shows great promise in modulating key neurotransmitter systems involved in mental health conditions like PTSD. By targeting serotonin, dopamine, and noradrenaline reuptake, this pharmacological testing could unlock new therapeutic pathways for addressing trauma-related disorders." True frontier stuff. Just a tad punchy, on the R/R scales...! In the meantime, expecting new chairman Dennis Purcell to swiftly open doors to further collaborations and investment. For me, a momentum play in its nascent stages. Tiny mkt cap (£4m at 0.18p), cashed up, and new mgmt and shareholders with big ideas to grow this vehicle. |
Posted at 03/7/2024 15:20 by bozzy_s Easy profit? For those who bought at 0.1p perhaps. But I wouldn't call it easy. It's 20% for now, for a tiny number of shares.The shares are worth 0.1p - that's what the company has valued itself at. This premium share price won't stay for long (currently 0.12-0.15 spread, so asking buyers to pay a 50% premium vs almost all the other shareholders. Why would anyone in their right mind do that?). Always seems to be the case when a company utterly screws its shareholders in a placing, they 'forget' to include the line 'the placing price represents a discount of xx% to the latest closing price'. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
